Janux Therapeutics Inc [JANX] stock is trading at $50.01, up 7.48%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JANX shares have gain 21.21% over the last week, with a monthly amount glided 24.50%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on September 06, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $70. Previously, Scotiabank started tracking the stock with Sector Perform rating on May 30, 2024, and set its price target to $47. On March 21, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $62 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $100 on March 20, 2024. Wedbush initiated its recommendation with a Outperform and recommended $24 as its price target on April 06, 2023.
Janux Therapeutics Inc [JANX] stock has fluctuated between $5.65 and $65.60 over the past year. Currently, Wall Street analysts expect the stock to reach $59.25 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $50.01 at the most recent close of the market. An investor can expect a potential return of 18.48% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 15.13M for the trailing twelve months, which represents a growth of 741.72%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -4.36%, Pretax Profit Margin comes in at -2.91%, and Net Profit Margin reading is -2.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.09 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.43 points at the first support level, and at 44.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.61, and for the 2nd resistance point, it is at 53.20.
Ratios To Look Out For
For context, Janux Therapeutics Inc’s Current Ratio is 57.34. Also, the Quick Ratio is 57.34, while the Cash Ratio stands at 1.27. Considering the valuation of this stock, the price to sales ratio is 172.41, the price to book ratio is 3.97.
Transactions by insiders
Recent insider trading involved Lichter Jay, FORMER DIRECTOR, that happened on Sep 13 ’24 when 3815.0 shares were purchased. 10% Owner, Avalon BioVentures I, LP completed a deal on Sep 12 ’24 to buy 30613.0 shares. Meanwhile, 10% Owner Avalon BioVentures SPV I, L.P. bought 0.16 million shares on Sep 12 ’24.
